"We're excited to become a clinical-stage biotech company; it's exciting from an AI drug discovery standpoint," says Absci founder and CEO Sean McClain. AbsciArtificial intelligence has been working its way into the drug development process for years now, but with little to show so far in revamping the notoriously burdensome process. While drugs are being developed using AI in a variety of ways, no drugs developed completely by AI, from start to…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.